| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 9 | 2021 | 207 | 2.660 |
Why?
|
| Reperfusion Injury | 7 | 2016 | 49 | 2.430 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 4 | 2017 | 124 | 1.770 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2021 | 168 | 1.750 |
Why?
|
| Liver Neoplasms | 8 | 2021 | 277 | 1.640 |
Why?
|
| Liver | 6 | 2017 | 796 | 1.290 |
Why?
|
| Living Donors | 4 | 2016 | 71 | 1.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 32 | 1.170 |
Why?
|
| Kidney | 4 | 2022 | 416 | 0.910 |
Why?
|
| Vasodilation | 4 | 2014 | 35 | 0.810 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2022 | 4 | 0.800 |
Why?
|
| End Stage Liver Disease | 2 | 2020 | 31 | 0.700 |
Why?
|
| Hepatic Artery | 1 | 2020 | 20 | 0.690 |
Why?
|
| Electronics | 2 | 2018 | 34 | 0.690 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2019 | 2 | 0.640 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 626 | 0.640 |
Why?
|
| Computers | 1 | 2019 | 49 | 0.630 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 251 | 0.570 |
Why?
|
| Nitric Oxide | 4 | 2013 | 146 | 0.570 |
Why?
|
| PPAR alpha | 1 | 2017 | 29 | 0.550 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 35 | 0.550 |
Why?
|
| NF-kappa B | 2 | 2016 | 458 | 0.550 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 41 | 0.540 |
Why?
|
| Acetaminophen | 1 | 2017 | 49 | 0.540 |
Why?
|
| Endotoxemia | 1 | 2016 | 11 | 0.540 |
Why?
|
| Protective Agents | 1 | 2016 | 9 | 0.540 |
Why?
|
| Animals | 26 | 2024 | 19601 | 0.530 |
Why?
|
| Biliary Atresia | 1 | 2016 | 2 | 0.530 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 25 | 0.530 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2014 | 26 | 0.520 |
Why?
|
| Apoptosis | 4 | 2014 | 1032 | 0.510 |
Why?
|
| Body Weight | 2 | 2015 | 368 | 0.500 |
Why?
|
| Interferon-alpha | 2 | 2013 | 99 | 0.490 |
Why?
|
| Endothelium, Vascular | 4 | 2014 | 169 | 0.490 |
Why?
|
| Synapses | 1 | 2017 | 178 | 0.490 |
Why?
|
| alpha-Fetoproteins | 2 | 2014 | 15 | 0.480 |
Why?
|
| Natural Killer T-Cells | 1 | 2015 | 27 | 0.480 |
Why?
|
| Male | 26 | 2020 | 27727 | 0.480 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 6 | 0.470 |
Why?
|
| Acidosis | 1 | 2014 | 26 | 0.460 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 132 | 0.460 |
Why?
|
| CA-19-9 Antigen | 1 | 2014 | 10 | 0.460 |
Why?
|
| Liver Diseases | 1 | 2015 | 138 | 0.440 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 124 | 0.430 |
Why?
|
| Mice | 12 | 2024 | 10251 | 0.430 |
Why?
|
| Tissue Donors | 1 | 2014 | 143 | 0.430 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 2046 | 0.420 |
Why?
|
| Recovery of Function | 1 | 2014 | 270 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 179 | 0.410 |
Why?
|
| Thymidine Phosphorylase | 1 | 2012 | 4 | 0.400 |
Why?
|
| Floxuridine | 1 | 2012 | 4 | 0.400 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 13 | 0.390 |
Why?
|
| Aorta, Thoracic | 3 | 2014 | 81 | 0.380 |
Why?
|
| Proteins | 2 | 2016 | 730 | 0.370 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 349 | 0.370 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 10 | 0.360 |
Why?
|
| Ischemic Postconditioning | 1 | 2010 | 3 | 0.360 |
Why?
|
| Triterpenes | 1 | 2010 | 21 | 0.350 |
Why?
|
| Brain | 1 | 2019 | 1487 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 475 | 0.350 |
Why?
|
| Mice, Knockout | 4 | 2017 | 1985 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2014 | 574 | 0.350 |
Why?
|
| Rats | 10 | 2014 | 1909 | 0.350 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 215 | 0.340 |
Why?
|
| Kidney Diseases | 1 | 2012 | 169 | 0.340 |
Why?
|
| Hepatectomy | 1 | 2010 | 60 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 5 | 2022 | 3220 | 0.340 |
Why?
|
| Aorta | 2 | 2010 | 108 | 0.330 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 85 | 0.330 |
Why?
|
| Treatment Outcome | 8 | 2021 | 5283 | 0.320 |
Why?
|
| Infant | 3 | 2020 | 1486 | 0.310 |
Why?
|
| Child, Preschool | 3 | 2020 | 1782 | 0.300 |
Why?
|
| rho-Associated Kinases | 1 | 2007 | 11 | 0.290 |
Why?
|
| Robotics | 2 | 2020 | 69 | 0.290 |
Why?
|
| Oxidative Stress | 3 | 2017 | 279 | 0.290 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2007 | 32 | 0.290 |
Why?
|
| Amides | 1 | 2007 | 52 | 0.290 |
Why?
|
| Pyridines | 1 | 2007 | 98 | 0.280 |
Why?
|
| Niacinamide | 2 | 2018 | 32 | 0.280 |
Why?
|
| Phenylurea Compounds | 2 | 2018 | 30 | 0.270 |
Why?
|
| Female | 17 | 2024 | 30696 | 0.270 |
Why?
|
| Genistein | 1 | 2006 | 9 | 0.270 |
Why?
|
| Bufanolides | 1 | 2006 | 1 | 0.260 |
Why?
|
| Humans | 21 | 2022 | 59285 | 0.250 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 64 | 0.250 |
Why?
|
| Hepatocytes | 2 | 2017 | 196 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 396 | 0.240 |
Why?
|
| Transfection | 3 | 2017 | 675 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 194 | 0.240 |
Why?
|
| Deferoxamine | 1 | 2024 | 4 | 0.240 |
Why?
|
| Phenylenediamines | 1 | 2024 | 5 | 0.240 |
Why?
|
| Decidua | 1 | 2024 | 3 | 0.240 |
Why?
|
| Graft Rejection | 2 | 2017 | 289 | 0.230 |
Why?
|
| Stromal Cells | 1 | 2024 | 65 | 0.230 |
Why?
|
| Biphenyl Compounds | 2 | 2015 | 31 | 0.230 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2014 | 38 | 0.220 |
Why?
|
| Microcirculation | 2 | 2014 | 52 | 0.220 |
Why?
|
| Child | 3 | 2020 | 4173 | 0.220 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 63 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 2 | 2014 | 138 | 0.220 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 228 | 0.220 |
Why?
|
| Cell Hypoxia | 3 | 2013 | 42 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2017 | 2888 | 0.210 |
Why?
|
| Renal Circulation | 2 | 2013 | 11 | 0.210 |
Why?
|
| Time Factors | 4 | 2017 | 3614 | 0.210 |
Why?
|
| RNA Helicases | 1 | 2023 | 88 | 0.200 |
Why?
|
| Adolescent | 3 | 2020 | 5822 | 0.200 |
Why?
|
| Survival Rate | 3 | 2015 | 802 | 0.200 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 201 | 0.200 |
Why?
|
| Mutation | 3 | 2023 | 2452 | 0.200 |
Why?
|
| Urinary Calculi | 1 | 2022 | 2 | 0.200 |
Why?
|
| Urolithiasis | 1 | 2022 | 4 | 0.200 |
Why?
|
| Concanavalin A | 1 | 2022 | 40 | 0.200 |
Why?
|
| Constriction, Pathologic | 2 | 2020 | 112 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 631 | 0.200 |
Why?
|
| Anastomosis, Surgical | 2 | 2020 | 107 | 0.200 |
Why?
|
| Follistatin-Related Proteins | 1 | 2022 | 22 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2020 | 6071 | 0.200 |
Why?
|
| Myocardium | 2 | 2017 | 264 | 0.200 |
Why?
|
| Th17 Cells | 1 | 2022 | 57 | 0.190 |
Why?
|
| Glutamine | 1 | 2022 | 46 | 0.190 |
Why?
|
| China | 3 | 2018 | 134 | 0.190 |
Why?
|
| In Vitro Techniques | 4 | 2014 | 469 | 0.190 |
Why?
|
| Exosomes | 1 | 2022 | 44 | 0.190 |
Why?
|
| DNA Helicases | 1 | 2023 | 187 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 117 | 0.190 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1547 | 0.180 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 69 | 0.180 |
Why?
|
| Hypertension | 1 | 2006 | 567 | 0.180 |
Why?
|
| Microbiota | 1 | 2022 | 104 | 0.180 |
Why?
|
| Mammals | 1 | 2022 | 208 | 0.180 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2020 | 8 | 0.180 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2020 | 12 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2016 | 583 | 0.170 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 31 | 0.170 |
Why?
|
| Bacteria | 1 | 2023 | 279 | 0.170 |
Why?
|
| Neural Prostheses | 1 | 2020 | 1 | 0.170 |
Why?
|
| Microsurgery | 1 | 2020 | 51 | 0.170 |
Why?
|
| Afferent Pathways | 1 | 2020 | 17 | 0.170 |
Why?
|
| RNA Interference | 2 | 2013 | 590 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 730 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1151 | 0.160 |
Why?
|
| Middle Aged | 8 | 2016 | 16311 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 203 | 0.150 |
Why?
|
| Receptors, Artificial | 1 | 2018 | 2 | 0.150 |
Why?
|
| Adult | 7 | 2018 | 15664 | 0.150 |
Why?
|
| Adaptation, Biological | 1 | 2018 | 15 | 0.150 |
Why?
|
| Nociceptors | 1 | 2018 | 9 | 0.150 |
Why?
|
| Thrombosis | 1 | 2020 | 181 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2016 | 1470 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2015 | 1202 | 0.140 |
Why?
|
| Oxygen | 3 | 2015 | 313 | 0.140 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2015 | 18 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 300 | 0.140 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 6 | 0.140 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 75 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 22 | 0.140 |
Why?
|
| Luciferases | 1 | 2017 | 106 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 365 | 0.140 |
Why?
|
| Galactosamine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Risk Factors | 3 | 2016 | 4982 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 163 | 0.140 |
Why?
|
| Phylogeny | 1 | 2018 | 336 | 0.140 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2014 | 9 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 118 | 0.130 |
Why?
|
| Postoperative Period | 2 | 2014 | 127 | 0.130 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 50 | 0.130 |
Why?
|
| Genes, Reporter | 1 | 2017 | 239 | 0.130 |
Why?
|
| Geobacter | 1 | 2016 | 12 | 0.130 |
Why?
|
| Nanowires | 1 | 2016 | 8 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2017 | 2089 | 0.130 |
Why?
|
| Acetylation | 1 | 2016 | 112 | 0.130 |
Why?
|
| Electric Conductivity | 1 | 2016 | 52 | 0.130 |
Why?
|
| Liver Failure | 1 | 2016 | 17 | 0.130 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 50 | 0.130 |
Why?
|
| Integrases | 1 | 2016 | 36 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 140 | 0.130 |
Why?
|
| beta Catenin | 1 | 2016 | 86 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2337 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 616 | 0.130 |
Why?
|
| Bile Duct Diseases | 1 | 2015 | 9 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2015 | 21 | 0.130 |
Why?
|
| Torsion Abnormality | 1 | 2015 | 12 | 0.130 |
Why?
|
| Organ Size | 1 | 2015 | 164 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2015 | 16 | 0.120 |
Why?
|
| Graft Survival | 1 | 2016 | 290 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2017 | 162 | 0.120 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2015 | 14 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 40 | 0.120 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2014 | 1 | 0.120 |
Why?
|
| Hydrochloric Acid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Tracheophyta | 1 | 2014 | 1 | 0.120 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 150 | 0.120 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2016 | 250 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 78 | 0.110 |
Why?
|
| Perioperative Period | 1 | 2014 | 19 | 0.110 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 108 | 0.110 |
Why?
|
| Lamiaceae | 1 | 2014 | 3 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2014 | 103 | 0.110 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 4 | 0.110 |
Why?
|
| Flavonoids | 1 | 2014 | 73 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2014 | 142 | 0.110 |
Why?
|
| Extracellular Space | 1 | 2013 | 29 | 0.110 |
Why?
|
| Nitric Oxide Donors | 1 | 2013 | 5 | 0.110 |
Why?
|
| Warm Ischemia | 1 | 2013 | 3 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 21 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 688 | 0.110 |
Why?
|
| Hypoxia | 1 | 2014 | 112 | 0.110 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 15 | 0.110 |
Why?
|
| Etoposide | 1 | 2013 | 33 | 0.110 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 22 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1368 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 46 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 409 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 70 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 79 | 0.110 |
Why?
|
| Flavones | 1 | 2014 | 53 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2014 | 180 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 87 | 0.100 |
Why?
|
| Inflammasomes | 1 | 2016 | 324 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 743 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 674 | 0.100 |
Why?
|
| Lipocalins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 21 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 179 | 0.100 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Kidney Tubules | 1 | 2012 | 18 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 173 | 0.100 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 34 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2014 | 384 | 0.100 |
Why?
|
| Protein Binding | 1 | 2016 | 1554 | 0.100 |
Why?
|
| Incidence | 1 | 2015 | 1236 | 0.100 |
Why?
|
| DNA | 1 | 2016 | 806 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 902 | 0.100 |
Why?
|
| Indomethacin | 2 | 2014 | 19 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 86 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2017 | 846 | 0.090 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 60 | 0.090 |
Why?
|
| DNA Damage | 1 | 2013 | 279 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1283 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1025 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1051 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 324 | 0.090 |
Why?
|
| Potassium Channel Blockers | 2 | 2010 | 24 | 0.090 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2010 | 6 | 0.090 |
Why?
|
| Ligation | 1 | 2010 | 33 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 76 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 650 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 57 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 318 | 0.090 |
Why?
|
| Carotenoids | 1 | 2010 | 66 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2013 | 399 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 221 | 0.080 |
Why?
|
| Mitochondria, Heart | 2 | 2014 | 13 | 0.080 |
Why?
|
| Young Adult | 2 | 2016 | 4266 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2013 | 696 | 0.080 |
Why?
|
| rhoC GTP-Binding Protein | 1 | 2007 | 3 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 27 | 0.070 |
Why?
|
| ras Proteins | 1 | 2007 | 77 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 855 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 188 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2007 | 137 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 250 | 0.070 |
Why?
|
| Rats, Inbred SHR | 1 | 2006 | 5 | 0.070 |
Why?
|
| Nitroprusside | 1 | 2006 | 7 | 0.070 |
Why?
|
| Rats, Inbred WKY | 1 | 2006 | 11 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2006 | 10 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2006 | 41 | 0.070 |
Why?
|
| Pregnancy | 2 | 2024 | 2202 | 0.070 |
Why?
|
| Actins | 1 | 2007 | 258 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2006 | 21 | 0.060 |
Why?
|
| Heat Shock Transcription Factors | 2 | 2016 | 12 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 1552 | 0.060 |
Why?
|
| Cyclohexylamines | 1 | 2024 | 5 | 0.060 |
Why?
|
| Heart Rate | 1 | 2006 | 307 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1464 | 0.060 |
Why?
|
| Embryo Implantation | 1 | 2024 | 21 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 29 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 294 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2006 | 495 | 0.060 |
Why?
|
| Iron | 1 | 2024 | 136 | 0.060 |
Why?
|
| KATP Channels | 1 | 2003 | 1 | 0.050 |
Why?
|
| RNA Recognition Motif Proteins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2023 | 47 | 0.050 |
Why?
|
| Cytoplasmic Granules | 1 | 2023 | 50 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 81 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 88 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2015 | 197 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 2 | 2014 | 45 | 0.050 |
Why?
|
| Plasmids | 1 | 2023 | 279 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2022 | 9 | 0.050 |
Why?
|
| Follistatin | 1 | 2022 | 44 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 55 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 130 | 0.050 |
Why?
|
| Sirolimus | 1 | 2021 | 88 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2020 | 37 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 3065 | 0.040 |
Why?
|
| Niobium | 1 | 2020 | 1 | 0.040 |
Why?
|
| Mechanoreceptors | 1 | 2020 | 13 | 0.040 |
Why?
|
| Oxides | 1 | 2020 | 33 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 56 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 410 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 523 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 162 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 329 | 0.040 |
Why?
|
| Livestock | 1 | 2018 | 1 | 0.040 |
Why?
|
| Methicillin Resistance | 1 | 2018 | 21 | 0.040 |
Why?
|
| Diffusion | 1 | 2018 | 82 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 63 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2018 | 58 | 0.040 |
Why?
|
| Virulence | 1 | 2018 | 186 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2018 | 80 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 142 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 304 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2018 | 189 | 0.030 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2017 | 33 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 44 | 0.030 |
Why?
|
| Biofilms | 1 | 2018 | 70 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 116 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2016 | 19 | 0.030 |
Why?
|
| Tryptophan | 1 | 2016 | 54 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 191 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 617 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2017 | 174 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 236 | 0.030 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 12 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 146 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1094 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2015 | 28 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 283 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 155 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 68 | 0.030 |
Why?
|
| Cholestasis | 1 | 2015 | 53 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 26 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 868 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 551 | 0.030 |
Why?
|
| Testosterone | 1 | 2015 | 112 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 272 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1137 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 2014 | 60 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2014 | 24 | 0.030 |
Why?
|
| DEAD Box Protein 58 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 30 | 0.030 |
Why?
|
| Heterografts | 1 | 2013 | 61 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 258 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 716 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2013 | 81 | 0.030 |
Why?
|
| Neuroglia | 1 | 2013 | 79 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 176 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 882 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 806 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 452 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 194 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 141 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 128 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 846 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 266 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2010 | 14 | 0.020 |
Why?
|
| Glucose | 1 | 2013 | 445 | 0.020 |
Why?
|
| Vitamin A | 1 | 2010 | 25 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 13412 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 461 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1599 | 0.020 |
Why?
|
| Neurons | 1 | 2013 | 863 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 1305 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2003 | 230 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 111 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2003 | 253 | 0.010 |
Why?
|